Despoina Piatopoulou

Despoina Piatopoulou

Auto-generated profile, based on publicly available information

Despoina Piatopoulou

Laboratory of Clinical Biochemistry-Molecular Diagnostics, 2nd Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, 'P &A Kyriakou' Children's Hospital, Levadias 13 Street, Athens 11527, Greece

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2017 in British Journal of Cancer
Verified
Journal Article
Open access
DPDespina Piatopoulou
Despina Piatopoulou
Margaritis AvgerisMargaritis Avgeris
Margaritis Avgeris
AMAntonios Marmarinos
Antonios Marmarinos
MXMarieta Xagorari
Marieta Xagorari
MBMargarita Baka
Margarita Baka
DGDimitrios Gourgiotis
Dimitrios Gourgiotis
Background: Despite the favourable survival rates of childhood acute lymphoblastic leukaemia (ALL), a significant number of patients present resistance to antileukaemic agents and dismal prognosis. In this study, we analysed miR-125b expression in childhood ALL and evaluated its clinical utility for patients treated with Berlin-Frankfurt-Munster (BFM) protocol. Methods: The study included 272 bone marrow specimens obtained on diagnosis and on BFM day 33 from 125 patients and 64 healthy children. Following extraction, RNA was polyadenylated and reverse transcribed. miR-125b levels were quantified by quantitative PCR. Cytogenetics, immunohistotype and MRD were analysed according to international guidelines. Results: Downregulated miR-125b levels were detected in childhood ALL patients and correlated with adverse prognosis. Following BFM induction, miR-125b levels were significantly increased, however, elevated day 33/diagnosis miR-125b ratio was associated with unfavourable disease features. Loss of miR-125b during diagnosis and higher day 33/diagnosis ratio were correlated with stronger risk for disease short-term relapse and patients' worse survival. Moreover, multivariate regression models highlighted the independent prognostic value of miR-125b for childhood ALL. Finally, the combination of miR-125b with clinically used disease markers clearly enhanced the prediction of patients' resistance to BFM chemotherapy. Conclusions: miR-125b significantly improves the prognosis of childhood ALL patients' outcome under BFM treatment.

1 February 2013 in Cytokine
Verified
Journal Article
Closed access
TBTheodora Boutsikou
Theodora Boutsikou
DBDespina D. Briana
Despina D. Briana
MBMaria Boutsikou
Maria Boutsikou
GKGeorge Kafalidis
George Kafalidis
DPDespoina Piatopoulou
Despoina Piatopoulou
AMAriadne Malamitsi-Puchner
Ariadne Malamitsi-Puchner

16 May 2015 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
LSLamprini Stamati
Lamprini Stamati
Margaritis AvgerisMargaritis Avgeris
Margaritis Avgeris
HKHelen Kosmidis
Helen Kosmidis
MBMargarita Baka
Margarita Baka
TATheodora Anastasiou
Theodora Anastasiou
DGDimitrios Gourgiotis
Dimitrios Gourgiotis

9 April 2014 in Journal of Perinatal Medicine
Verified
Journal Article
Closed access
TBTheodora Boutsikou
Theodora Boutsikou
MGMaria Giotaki
Maria Giotaki
MBMaria Boutsikou
Maria Boutsikou
DBDespina D. Briana
Despina D. Briana
SBStavroula Baka
Stavroula Baka
AMAriadne Malamitsi-Puchner
Ariadne Malamitsi-Puchner
Objective: To determine levels of galectins (gal)-1 and -3 (implicated in angiogenesis/immunologic mechanisms) in intrauterine growth restricted (IUGR), large (LGA) and appropriate for gestational age (AGA) pregnancies, as these groups differ in fat mass, angiogenic patterns and immune responses. Methods: Cord-blood (UC) gal-1 and -3 concentrations were measured in 30 IUGR, 30 LGA and 20 AGA singleton full-term infants and their mothers (MS). Results: IUGR, LGA and AGA groups did not differ in gal-1 and -3 concentrations. UC gal-1 levels were lower when mothers were older [b=–0.651, CI 95% –1.186 (–0.116), P=0.018] and UC gal-3 levels were increased when mothers presented gestational diabetes [b=9.836, CI 95% 3.833- (15.839), P=0.002]. In IUGRs MS gal-3 and in LGAs UC gal-1 were decreased in multiparas [b=–5.372, CI 95% -9.584- (–1.161), P=0.014], and [b=–7.540, CI 95% -14.606- (–0.473), P=0.037], respectively. No correlations were found between MS or UC gal-1 and gal-3 concentrations. Conclusions: Lower UC gal-1 levels, when mothers were older, and increased UC gal-3 levels in cases of gestational diabetes, possibly reflect angiogenic activity. In multiparas, decreased MS gal-3 and UC gal-1 levels in IUGR/LGA, respectively, might imply inflammatory response against immunosuppression expected in subsequent pregnancies, as compared to the first one.